TPIRC

A Rare Disease Institute 🦋
Restoring hope. Advancing discovery. Empowering communities.

Orphan diseases include rare diseases that affect fewer than 200,000 people in the United States (such as cystic fibrosis) and more common conditions that have been neglected by the pharmaceutical industry (including food allergy). Because the pharmaceutical industry lacks the financial incentive to research, develop, and deliver treatment options for orphan conditions, patients have largely been

ignored by the traditional medical community. TPIRC (the Translational Pulmonary and Immunology Research Center) provides a medical home that advances advocacy, research, and clinical care and gives people with orphan conditions hope for a better life.

08/28/2026

We asked people online: “What do you wish your doctor told you about allergies?” Dr. Inderpal Randhawa is here to answer.

A lot of people spend years managing environmental allergy symptoms without ever knowing there’s more than one long-term path to real relief. Here’s the breakdown:

💉 Allergy shots — the actual environmental allergen, injected to retrain your immune system not to react. Typically 5 to 10 years of treatment, depending on the case.

💧 SLIT (sublingual immunotherapy) — environmental allergy drops taken at home, no needles. Most people feel improvement in about 6 months, with treatment generally done in around 5 years.

At TPIRC and LAHA, Dr. Randhawa and the team use big data to understand exactly how these therapies work for each patient, not just what helps them improve faster, but how long they’ll actually need treatment. Because cost matters, and you shouldn’t be on a therapy for a decade without understanding why.

Want to learn more about SLIT to treat your environmental allergies? Check out LAHA | Lung and Allergy Health Associates to find out if it’s right for you.

Got a question about your allergies? Drop it below. 👇

AllergyShots

08/26/2026

Most food allergy lab tests look at an allergen as a whole and simply tell you to stay away from it. At Aperture ImmunoDiagnostics, we go deeper.

Take peanuts: within that single allergen are 14 distinct proteins. Out of the ~80-90 tests available industry-wide, we run about 66% of them, most other labs won’t even carry.

But testing more isn’t enough on its own. A lab can run a single test and hope a physician catches any error, or run multiple tests for the same question and use AI/ML to validate the accuracy. We choose the latter, every time.

That precision is what powers the Tolerance Induction Program: by identifying exactly which proteins you react to and how they relate to each other, we build real tolerance, so your body already has a defense before you ever take a bite.

“I really care about what we do here... you really see the patient, the person on the other side, as opposed to just a test tube.”

That’s the difference between managing a diagnosis and guiding someone to food freedom.

08/18/2026

Food allergies don’t stop at 18. But most OIT programs do.

A 2026 survey of the FARE Clinical Network found that only 9 of 32 participating centers offer oral immunotherapy to adult patients. That’s not a gap. That’s a pattern.

Pediatric care has driven the field forward for years, and rightfully so. But somewhere along the way, adults were left out of the room. The result: a generation of patients who aged out of childhood treatment and into a system that mostly stopped looking for them.

This isn’t just a stat in a research paper. It’s a design flaw in how the field has approached food allergy care.

Share this with someone who’s in this boat. Tap the link in our bio to learn more about what we do.

Source: Ponda P, Bird JA, Bufford JL, et al. Food Oral Immunotherapy Patient Selection, Dosing, and Monitoring Practices Among a Network of US Food Allergy Centers. J Allergy Clin Immunol Pract. 2026.

08/14/2026

Back to school brings a lot to prepare for, and for food allergy families, that list is longer.

This checklist covers four things to have in place before day one: understanding your school’s food allergy plan (including 504 protections), cafeteria safety, communicating with teachers and staff, and keeping emergency medications current and accessible.

One conversation now can prevent a scramble later.

Adapted from FAI’s Back to School Tips guide. Want more? Catch the recording of our recent Back-to-School webinar with TIP families for real stories and advice.

Save this checklist for your back-to-school prep, and share it with fellow allergy parents.

08/12/2026

Desensitization and remission both fall under “food allergy treatment,” but they’re not the same finish line.

Desensitization requires ongoing dosing, indefinitely, and even then, most patients still can’t eat their allergen freely. It’s real protection, just not freedom.

Remission is different: once in maintenance, patients often dose just once a week on average, sometimes once every 2-3 weeks. In between, they eat their former allergen in any amount, freely. That’s not just a higher tolerance. It’s the immune system reaching sustained unresponsiveness altogether.

At TPIRC and FAI, remission is the outcome we build every treatment plan toward.

08/10/2026

Depending on which clinic you walk into, OIT treatment can look completely different, because there’s no U.S. guideline defining how it should be done. Research confirms it: broadly adopted, but delivered with real inconsistency, center to center.

That’s exactly the gap FAI’s Food Lab exists to close. Every allergen gummy and TIP Tart is manufactured to a precise, repeatable dose. Each patient’s treatment plan stays built around their own diagnostic profile.

Today, we’re recognizing the team behind that work: the people who make sure standardization isn’t just a claim, it’s what happens in every gummy, every tart, every day.

Learn more about our Food Lab: foodallergyinstitute.com/food-lab

08/07/2026

What if treatment didn’t have to start with years of trial and error?

At TPIRC, it doesn’t. We call it the B.A.R.I.C. Data Loop — a closed system that powers care with data, personalizes treatment, and accelerates recovery for patients facing rare and orphan diseases.

It starts in our Biobank, an IRB-approved repository of clinical data. Our Analytics team runs real-time diagnostics to find patterns. Research builds on those patterns to understand how a disease behaves and how patients respond to therapy. Informatics turns those findings into standards. And in Clinical remission, that becomes real, personalized treatment.

Then it loops — every step feeds back into the Biobank, mitigating risk and accelerating recovery for the next patient.

This is what happens when big data meets big medicine.

Follow Translational Pulmonary and Immunology Research Center as we unpack this loop

07/31/2026

“We think this is what you have. Here’s an EpiPen. Good luck.”

That’s the honest answer a lot of people get when their symptoms don’t fit a standard test. For conditions like FPIES, that’s more common than you’d think.

FPIES is a real, diagnosable allergic condition that often won’t show up on a typical skin or blood test. It can develop at any age, even to a food you’ve eaten your whole life without issue. Alpha-Gal syndrome is another example, a reaction to red meat that can appear seemingly out of nowhere in people who were otherwise completely fine.
Different conditions, same frustrating gap: the diagnostic tools haven’t caught up to what patients are actually living through.
That gap is exactly what TPIRC was built to close. Using data, mathematics, and AI to find better answers where standard testing falls short.

Content for educational purposes.

07/24/2026

Meet the team engineering the future of food allergy treatment, one tablet at a time.

Peanut allergy treatment makes up nearly 20% of all the dosing products produced in our Food Lab. We sat down with Shin Nagane, our Manager of Research & Product Development, to talk about the “why” behind the Peanut TIP Tart: a chewable tablet built from the ground up to be kosher and vegan-friendly, free of artificial dyes and flavors, and precisely matched to the same trusted dosing patients already rely on.

This wasn’t a small tweak. It was a rebuild, from formulation to packaging, designed around real feedback from real patients navigating daily treatment.

Our Hazelnut TIP Tart proved this model works. Peanut is next, and it’s our biggest tablet launch yet.

This is what it looks like when a research institute doesn’t stop at developing a treatment. It keeps re-engineering how that treatment reaches the people who need it.

Follow along as we keep pushing it forward.

07/22/2026

50% of kids with eczema go on to develop asthma. 1 in 3 develop food allergies along the way. Doctors call this the “allergic march.”

At TPIRC, understanding how these conditions connect — not just treating them one at a time — is central to our research. That understanding is put into practice across our ecosystem: LAHA | Lung and Allergy Health Associates , where allergists and pulmonologists see patients through eczema, rhinitis, and asthma together, and Food Allergy Institute , where our food allergy program helps kids build lasting tolerance instead of just managing symptoms.

Learn more about us at TPIRC.org - link in bio

Address

701 E 28th Street #419
Long Beach, CA
90806

Telephone

562-490-9900

Website

http://www.tpirc.org/, https://givebutter.com/fear-is-a-part-of-living-with-food-allergies-xf8yz4?utm_source=instagram&u

Alerts

Be the first to know and let us send you an email when TPIRC posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to TPIRC:

Want your organization to be the top-listed Non Profit Organization in Long Beach?